UBS Group
TMDX icon

UBS Group’s Transmedics TMDX Stock Holding History

UBS Group’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.4M Sell
488,058
-92,735
-16% -$7.85M ﹤0.01% 2188
2026
Q1 		$57.7M Sell
580,793
-78,503
-12% -$10.2M 0.01% 1505
2025
Q4 		$80.2M Sell
659,296
-196,767
-23% -$24.7M 0.01% 1188
2025
Q3 		$96.1M Buy
856,063
+379,925
+80% +$44.5M 0.02% 1052
2025
Q2 		$63.8M Sell
476,138
-265,197
-36% -$29.1M 0.01% 1294
2025
Q1 		$49.9M Buy
741,335
+151,093
+26% +$10.4M 0.01% 1485
2024
Q4 		$36.8M Buy
590,242
+530,990
+896% +$49.4M 0.01% 1735
2024
Q3 		$9.3M Buy
59,252
+26,841
+83% +$4.14M ﹤0.01% 2441
2024
Q2 		$4.88M Sell
32,411
-12,788
-28% -$1.53M ﹤0.01% 2898
2024
Q1 		$3.34M Buy
45,199
+4,936
+12% +$407K ﹤0.01% 3400
2023
Q4 		$3.18M Buy
40,263
+16,309
+68% +$984K ﹤0.01% 3296
2023
Q3 		$1.31M Buy
23,954
+20,904
+685% +$1.5M ﹤0.01% 3849
2023
Q2 		$256K Sell
3,050
-11,286
-79% -$864K ﹤0.01% 5315
2023
Q1 		$1.09M Buy
14,336
+4,472
+45% +$309K ﹤0.01% 4033
2022
Q4 		$609K Buy
9,864
+6,786
+220% +$361K ﹤0.01% 4531
2022
Q3 		$128K Sell
3,078
-576
-16% -$25.1K ﹤0.01% 5495
2022
Q2 		$115K Sell
3,654
-9,989
-73% -$266K ﹤0.01% 5315
2022
Q1 		$367K Sell
13,643
-11,692
-46% -$209K ﹤0.01% 4915
2021
Q4 		$486K Buy
25,335
+22,310
+738% +$559K ﹤0.01% 5010
2021
Q3 		$100K Buy
3,025
+675
+29% +$20.6K ﹤0.01% 5832
2021
Q2 		$78K Sell
2,350
-1,199
-34% -$33.2K ﹤0.01% 6072
2021
Q1 		$148K Sell
3,549
-5,729
-62% -$176K ﹤0.01% 5674
2020
Q4 		$184K Buy
9,278
+1,548
+20% +$22.9K ﹤0.01% 5290
2020
Q3 		$106K Sell
7,730
-5,888
-43% -$101K ﹤0.01% 5146
2020
Q2 		$244K Sell
13,618
-896
-6% -$14K ﹤0.01% 4661
2020
Q1 		$175K Sell
14,514
-8,330
-36% -$140K ﹤0.01% 4824
2019
Q4 		$434K Buy
22,844
+11,348
+99% +$208K ﹤0.01% 4961
2019
Q3 		$273K Buy
11,496
+4,700
+69% +$113K ﹤0.01% 5015
2019
Q2 		$197K Buy
+6,796
New +$186K ﹤0.01% 4925

Other funds holding TMDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

UBS Group's TMDX Position: Q2 2026 in Review

UBS Group reduced its Transmedics (TMDX) stake by 16% in Q2 2026, selling an estimated $7.85M and leaving 488,058 shares worth $32.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2188.

UBS Group first reported a position in TMDX in Q2 2019 and has held it in 29 quarters since. The position peaked at $96.1M in Q3 2025. 374 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

  • UBS Group held 488,058 shares of Transmedics worth $32.4M as of Q2 2026.
  • UBS Group sold 92,735 Transmedics shares in Q2 2026, an estimated $7.85M.
  • Transmedics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2188 holding.
  • UBS Group first reported a position in Transmedics in Q2 2019 and has held it in 29 quarters since.
  • UBS Group's Transmedics position peaked at $96.1M in Q3 2025.
  • 374 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.